Non-muscle invasive bladder cancer (NMIBC) is often described as the ‘manageable’ form of bladder cancer. It does not invade muscle, it is frequently treatable, and survival outcomes are generally favourable. Yet, that label hides a more complex reality.

For many patients, NMIBC is not a one-off diagnosis; it is a long-term condition defined by recurrence, repeated procedures, and ongoing uncertainty. Up to 70% of patients experience recurrence after initial treatment, often requiring repeated surgeries and lifelong surveillance. Read more about NMIBC (PDF).

At the centre of this journey sits a treatment pathway that, until recently, has changed very little.

The traditional model: BCG or Cystectomy

For decades, treatment for NMIBC has followed a familiar structure.

After tumour removal via transurethral bladder tumour resection (TURBT), patients are stratified by risk. Low-risk disease may require only surveillance or intravesical chemotherapy. For high-risk disease, the cornerstone has been intravesical Bacillus Calmette–Guérin (BCG) therapy.

BCG works by stimulating a local immune response within the bladder, reducing recurrence and progression. It remains highly effective, but not universally so.

Up to 40% of patients either do not respond or eventually become BCG-unresponsive. This is a turning point in the treatment pathway.

The gold standard shifts to radical cystectomy, a life-altering surgery involving complete bladder removal. While clinically effective, it carries significant morbidity and impact on quality of life. Read more about treatment options for NMIBC.   

For many patients, the decision is not simply clinical, it is deeply personal.

This is precisely where current research is focused.

A field in transition: The rise of bladder-preserving therapies

Over the past decade, NMIBC research has shifted away from a binary choice, BCG or cystectomy, towards a more nuanced, patient-centred goal looking at how we can preserve the bladder without compromising cancer control.

This question is driving a wave of innovation across multiple domains.

A key turning point that helped stimulate the research landscape was the FDA’s issuance of draft guidance allowing single-arm clinical trials in the approval process for therapies targeting BCG-unresponsive NMIBC. This aimed to expedite drug development and shorten timelines. It was particularly important because randomized trials in this setting were often unethical or not feasible, for example, randomizing patients between a novel drug and a life-altering surgery such as cystectomy.

Immunotherapy

The success of checkpoint inhibitors in advanced cancers has translated into NMIBC research, particularly in BCG-unresponsive disease.

The KEYNOTE-057 trial demonstrated that pembrolizumab, a PD-1 inhibitor, can induce meaningful responses in patients with BCG-unresponsive NMIBC, offering a systemic, non-surgical option for patients unable or unwilling to undergo cystectomy. Read more about the KEYNOTE-057 trial.

Immunotherapy is also no longer being studied in isolation.

New trials are exploring combinations with BCG, aiming not to replace it, but to enhance it. The idea is simple but powerful: if BCG primes the immune response, can checkpoint inhibitors sustain and amplify it? The phase 3 CREST trial showed that Sasanlimab in combination with BCG significantly improved survival compared with BCG alone in BCG-naïve high-risk NMIBC, reducing the risk of recurrence or progression by about 32% with a manageable safety profile. Read more about the CREST trial.

This marks a shift from replacement strategies to optimisation strategies, refining what already works.

Gene therapy: Reprogramming the bladder environment

One of the exciting advances in NMIBC is the emergence of gene therapy. This approach represents an innovative concept in treatment.

Instead of repeatedly instilling treatment into the bladder, gene therapy allows the bladder itself to sustain the therapeutic effect.

Crestimogene Grenadenorepvec (CG0070) is an intravesical adenoviral vector-based gene therapy that selectively infects and lyses tumour cells, which stimulates release of cytokines and antigens that activates T-Cells, thereby promoting a further local anti-tumour immune response.

The phase 3 BOND-003 trial of CG0070 has shown promising efficacy, with complete response rates of almost 75% at any time and 46% at 12 months, alongside durable responses and a favourable safety profile with serious treatment-related adverse events reported. Read more about the BOND-003 trial.

Other clinical trials have demonstrated meaningful response rates in BCG-unresponsive disease, leading to regulatory approvals in some regions and signalling a major milestone in bladder cancer treatment. Adstiladrin (Nadofaragene Firedenovec-vncg) is the first gene therapy approved by the FDA in the United States for the treatment of patients with high-risk BCG-unresponsive NMIBC. This is not yet approved in the UK. 

Delivery methods: Same drugs, new look

Another important shift in NMIBC research is not necessarily about new drugs, but better ways of delivering existing ones.

Traditional intravesical chemotherapy is limited by one key issue: dwell time. Drugs are diluted and washed out by urine, reducing their effectiveness.

New technologies aim to overcome this. 

UGN-102: Mitomycin C in reverse thermal gel form provides prolonged drug contact with the bladder lining for up to 6 hours.

TAR-200: A pretzel-shaped drug-releasing devices that sits in the bladder and enables continuous Gemcitabine exposure over 3 weeks 

These innovations are subtle but significant. They move treatment from intermittent exposure to sustained therapy, potentially improving outcomes without increasing toxicity. Read more about Novel Treatment Delivery Methods.

Precision medicine in NMIBC

Historically, NMIBC has been treated as a relatively homogeneous disease. That assumption is now being challenged.

Targeted therapies such as FGFR inhibitors are being studied in patients with specific molecular alterations, introducing a more personalised approach to treatment. Oral Erdafitinib, a selective pan-FGFR inhibitor is already approved in the NHS for locally advanced or metastatic patients with susceptible FGFR3 alterations. It is currently being trialled as an intravesical instillation with NMIBC patients with FGFR mutations. Read more about Erdafitinib.

This reflects a broader shift seen across oncology, moving towards more personalised care.

Combination strategies: Where the field is heading

Perhaps the most important theme emerging across all these developments is combination therapy.

Rather than searching for a single breakthrough drug, current research is increasingly focused on combining:

Immunotherapy + intravesical therapy (e.g. Sasanlimab + BCG)

Gene therapy + checkpoint inhibitors (e.g. CG0070 + Pembrolizumab)

Chemotherapy + novel delivery systems (e.g. UGN-102, TAR-200, TAR210..)

The rationale is that effective treatment may require targeting multiple pathways simultaneously.

This mirrors progress seen in other cancers and suggests NMIBC is entering that same era of multi-modal early treatment intensification, and personalised care.

Read more about combination treatment strategies in NMIBC.

Where are we now?

Despite rapid progress, it is important to remain grounded.

BCG remains the standard of care for high-risk NMIBC. When used properly after complete resection of tumours, it provides results unmatched by any of the current new treatments being explored.  Radical cystectomy remains the definitive treatment for BCG-unresponsive disease.

The landscape is however changing. For the first time in decades, there are credible, evidence-based alternatives emerging, offering patients and clinicians more choice than ever before.

The bigger picture: Beyond survival

While much of the focus in oncology is rightly on survival outcomes, NMIBC presents a slightly different challenge. Patients often live with the disease for years. The burden is logistical, psychological, and quality-of-life driven. Repeated cystoscopies, hospital visits, and uncertainty about recurrence shape the patient experience just as much as the disease itself.

The shift towards bladder-preserving treatments is important. However, the goal is to avoid surgery while improving patients’ experience.

Looking ahead

The future of NMIBC treatment is unlikely to be defined by a single breakthrough.

Instead, it will be shaped by:

• Personalised treatment selection 
• Combination strategies 
• Improved drug delivery 
• Integration of patient-reported outcomes and a shift in mindset from treating disease alone to supporting the lived experience of patients.

The real progress in this field is the move from asking:

How do we control this cancer?

To asking:

How do we control it while preserving the patient’s quality of life, function, and dignity?